Abstract
Human hedgehog-interacting protein (HHIP), a negative regulator of the hedgehog (HH) signaling pathway, is frequently dysregulated in various cancers, including gastric cancer. This study investigates the inhibitory role of HHIP and the molecular mechanisms governing its regulation. We demonstrate that HHIP overexpression significantly suppresses the proliferation and invasion of AGS gastric cancer cells. Notably, methylation-specific PCR (MSP) revealed that HHIP overexpression dramatically reduces its own de novo promoter methylation levels. Clinical analysis showed that HHIP expression is significantly lower in gastric cancer tissues compared to adjacent non-cancerous tissues, and low HHIP levels correlate with increased metastasis. These findings suggest that HHIP modulates gastric cancer progression via a feedback mechanism involving promoter methylation, identifying HHIP as both a protective marker and a potential therapeutic target.
Introduction
The Hedgehog (HH) signaling pathway is a critical regulator of cell growth and differentiation. Hyperactivation of this pathway is a known driver of malignancies, including gastric cancer. HHIP serves as a natural antagonist to HH signaling, effectively acting as a molecular brake. While HHIP downregulation is observed in gastric cancer, the precise mechanisms of its silencing and its full functional impact on tumor progression remained poorly understood. This study aimed to elucidate HHIP's role in suppressing cancer progression and to investigate the epigenetic regulation—specifically CpG island methylation—that controls its expression.
Methods
The research team employed a multi-pronged approach combining clinical data with in vitro molecular biology:
- Cell Culture and Transduction: AGS human gastric cancer cells were transduced with a lentiviral vector (LV-HHIP) to induce stable HHIP overexpression.
- Functional Assays: Cell proliferation was assessed using MTT assays, and invasive potential was evaluated via Transwell assays.
- Epigenetic Analysis: Methylation-Specific PCR (MSP) and Bisulfite-Sequencing PCR (BSP) were employed to quantify DNA methylation levels at the HHIP promoter.
- Clinical Correlation: 52 pairs of gastric cancer and adjacent normal tissues were analyzed. Clinical outcomes, including metastasis and local recurrence, were tracked over a three-year follow-up period.
Results
HHIP Expression and Clinical Significance
Analysis of patient samples revealed that HHIP mRNA levels were significantly lower in gastric cancer tissues compared to normal adjacent tissues. Clinically, high HHIP expression was negatively correlated with distant metastasis ($p = 0.035$), although no significant correlation was found with local recurrence ($p = 0.58$). Patients with HHIP-positive tumors exhibited a significantly higher 3-year metastasis-free survival rate (88.6%) compared to those with HHIP-negative tumors (61.9%).
Suppression of Tumorigenic Properties
Lentiviral-mediated overexpression of HHIP in AGS cells resulted in a significant reduction in both cell proliferation and invasive capacity. Western blot analysis confirmed the successful expression of the HHIP fusion protein at approximately 58 kD.
The Epigenetic Feedback Loop
A key finding of this study is the discovery of an epigenetic feedback loop. In control AGS cells, the HHIP promoter was found to be almost entirely methylated (99.67%). Remarkably, the forced overexpression of HHIP led to a dramatic decrease in de novo promoter methylation, dropping to 13.85%. This suggests that HHIP protein levels can influence the epigenetic state of its own gene, potentially reinforcing its own expression.
Discussion
This study identifies HHIP as a potent tumor suppressor in gastric cancer that acts, in part, by preventing metastasis. The discovery of a "self-reinforcing" feedback loop, where HHIP protein expression reduces its own promoter methylation, provides a novel insight into cancer epigenetics. This mechanism suggests that therapeutic strategies aimed at restoring HHIP expression could be particularly effective, as the initial boost in expression might help overcome the epigenetic silencing that characterizes the disease state.
While these results are promising, limitations include the reliance on a single cell line (AGS) for mechanistic studies and the lack of in vivo animal models. Future research should focus on identifying the specific molecular mediators of the HHIP-induced demethylation and validating these findings in xenograft models to assess the feasibility of HHIP-based gene therapy.
Conclusion
HHIP plays a crucial role in suppressing the progression and metastasis of gastric cancer. Its expression is regulated by a feedback mechanism involving DNA methylation. Given its correlation with improved metastasis-free survival, HHIP serves as a valuable prognostic marker and a promising target for future therapeutic interventions in gastric cancer.
Summary updated